Últimas noticias sobre Akoya Biosciences (NASDAQ:AKYA) Bolsa

AKOYA BIOSCIENCES INC

Akoya Biosciences

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Akoya Biosciences Inc

On Wednesday, BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) announced a partnership with MicroDried, a provider of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44394003/branchout-food-signs-definitive-agreement-with-microdried-to-revolutionize-the-36-billion-dried-in" rel="noreferrer noopener">dried fruit and vegetable ingredients.</a>
This new venture is projected to generate $5 million-$6 million in annual ingredient sales, with the potential for further growth as demand for versatile and high-performance dried ingredients increases.
The collaboration integrates BranchOut&#8217;s GentleDry technology into MicroDried&#8217;s existing portfolio, expanding the range of ingredient solutions available to food manufacturers globally.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BOF stock has lost 15% in the past year.
The partnership will leverage BranchOut&#8217;s new 50,000 square-foot high-efficiency facility in Peru to drive large-scale production.
The global freeze-dried ingredient market, valued at $36 billion and growing annually at a 7.6% rate, is seeing an increasing demand for clean-label and cost-effective food solutions.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/offerings/25/03/44401708/whats-going-on-with-plug-power-stock-today-8" rel="noreferrer noopener">What&#8217;s Going On With Plug Power Stock Today?</a>
With this agreement, BranchOut aims to capture a share of this expanding market.
The partnership enhances MicroDried&#8217;s extensive ingredient portfolio, offering food manufacturers improved formulation flexibility and access to superior-quality dried ingredients.
The collaboration also aligns with the growing consumer preference for minimally processed foods and clean-label options.
With initial orders already in production, BranchOut and MicroDried are well-positioned to expand their influence in the global ingredient market, providing sustainable dried ingredient solutions to meet the needs of food manufacturers, according to the company&#8217;s statement.
Price Action: BOF shares are trading higher by 3.77% to $1.93 at last check Wednesday.
Image sourced from Shutterstock.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44401134/hutchmeds-oncology-revenue-hits-271-5-million-rising-65-on-fruzaqla-strength" target="_blank" rel="noreferrer noopener">Hutchmed&#8217;s Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength</a></li>
</ul>

Equities

News

Contracts

Markets

Movers

General

BranchOut's Partnership With MicroDried Expected To Boost Annual Sales By At Least $5 Million: Details

Royalty Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NYSE">RPRX</a>) short percent of float has fallen 10.08% since its last report. The company recently reported that it has 13.75 million shares sold short, which is 3.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Royalty Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742404527_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Royalty Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Royalty Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Royalty Pharma's peer group average for short interest as a percentage of float is 4.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

RPRX

How Do Investors Really Feel About Royalty Pharma?

Columbia Banking System's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NYSE">COLB</a>) short percent of float has risen 34.26% since its last report. The company recently reported that it has 7.24 million shares sold short, which is 3.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Columbia Banking System Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742404522_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Columbia Banking System has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Columbia Banking System's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Columbia Banking System's peer group average for short interest as a percentage of float is 3.70%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

COLB

Peering Into Columbia Banking System's Recent Short Interest

Anheuser-Busch InBev's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) short percent of float has risen 7.55% since its last report. The company recently reported that it has 4.93 million shares sold short, which is 0.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Anheuser-Busch InBev Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742404517_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Anheuser-Busch InBev has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Anheuser-Busch InBev's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Anheuser-Busch InBev's peer group average for short interest as a percentage of float is 5.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Anheuser-Busch InBev?

Athletic apparel and footwear company Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) could highlight a recent brand partnership, the impactof tariffs and progress under a new CEO when the company reports third-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Thursday.</a>
Here's a look at analyst estimates for the quarter, what analysts are saying and key items to watch.
Earnings Estimates: Analysts expect Nike to report third-quarter revenue of $11.01 billion, down from $12.43 billion according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company beat revenue estimates in the second quarter and has beaten analyst estimates for revenue in six of the last 10 quarters overall.
Analysts expect the company to report third-quarter earnings per share of 29 cents per share, down from 77 cents per share in last year's third quarter.
The company has beaten analyst estimates for earnings per share in six straight quarters and nine of the last 10 quarters overall.
What Analysts Are Saying: Needham analyst Tom Nikic sees minimal near-term risk to Nike estimates.
While he maintained a Market Perform rating and sees a strong near-term outlook, caution is given for fiscal 2026.
"We've realized upon building out our FY26 quarterly estimates that it will be difficult for NKE to achieve our prior out-year estimates," Nikic said.
The analyst lowered the price target from $84 to $80. "For 1H26, we expect another period of YoY decline in sales, margins, and EPS, followed by a return to growth in fiscal 2H26."
Nike stock may have found a floor with the hope that new CEO Elliott Hill can "right the ship," Nikic said, adding that the turnaround could take six months longer than originally thought.
Jefferies analyst Randal Konik <a href="https://www.benzinga.com/markets/25/02/43933841/nike-shares-set-for-a-turnaround-top-analyst-calls-for-aggressive-buy-amid-new-ceos-turnaround-plan">upgraded Nike stock</a> from Hold to Buy and called the company a "new top pick" last month.
The analyst put strong confidence in Hill and a turnaround strategy that could improve the company's wholesale business and key partnerships, along with new product innovation.
Konik raised the price target on Nike stock from $75 to $115. He said the current valuation of Nike's stock is the lowest its been in ten years, creating a potential "valuation floor" for shares.
&#8220;With shares near a valuation trough, we believe now is the right time to aggressively buy shares,&#8221; Konik said.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/02/44011416/nike-kim-kardashian-partnership-just-one-of-a-dozen-fixes-the-brand-needs-says-footwear-analyst">Nike-Kim Kardashian Partnership Just &#8216;One of a Dozen&#8217; Fixes The Brand Needs, Says Footwear Analyst</a>
Key Items to Watch: Nike recently <a href="https://www.benzinga.com/25/02/43789704/kim-kardashians-skims-joins-forces-with-nike-to-redefine-fitness-fashion-stock-gains">announced a new brand </a>called NikeSKIMS developed in partnership with shapewear company SKIMS, which was co-founded by Kim Kardashian.
The company could comment on how quickly these products will launch and what initial reception has looked like for the collaboration.
Nike aired its first Super Bowl commercial in more than two decades earlier this year. The commercial focused on female athletes. This could be a key topic for areas of growth for Nike going forward.
China could also be a key topic during the earnings release and management commentary. Greater China sales were down around 8% year-over-year in <a href="https://www.benzinga.com/general/sports/24/12/42605414/nike-q2-earnings-revenue-beat-eps-beat-shares-jump-nike-being-nike-again">the second quarter</a>, tied for the worse performing geographic region with North America.
Analysts and investors will be looking to see if China sales recover.
Tariffs will also be a key topic centered on China and other markets with Nike importing goods made in countries at risk to see higher tariffs in the future. Management will likely provide initial comments on being prepared for the higher costs and likelihood of short-term pressure.
If commentary is worse and provides details on higher costs for consumers or pressure on profit margins, the stock could take a hit. NKE Price Action: Nike stock is down 0.6% to $72.88 on Wednesday versus a 52-week trading range of $68.62 to $101.92. Nike stock is down 1.1% year-to-date in 2025, while shares have fallen over 27% in the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43756694/bill-ackmans-pershing-square-adjusts-portfolio-trims-chipotle-and-boosts-nike">Bill Ackman&#8217;s Pershing Square Adjusts Portfolio, Trims Chipotle and Boosts Nike</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Price Target

Previews

Reiteration

Analyst Ratings

Nike Q3 Earnings Preview: Analyst Says New CEO Can 'Right The Ship,' But It Could Take Longer Than Expected

Wedbush analyst Jay McCanless reiterated a <a target="_blank" href="https://www.benzinga.com/quote/len/analyst-ratings" rel="noreferrer noopener">Neutral rating</a> on Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) ahead of its first quarter <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">FY25 earnings release on March 20</a>.
For the first quarter, the analyst estimates EPS of $1.70 versus the Refinitiv consensus estimate of $1.75 and revenue of $7.5 billion (+3% YoY vs. cons. of +2% YoY). The estimates do not account for the <a target="_blank" href="https://www.benzinga.com//node/43625476" rel="noreferrer noopener">recent&nbsp;</a><a target="_blank" href="https://www.benzinga.com//node/43625476" rel="noreferrer noopener">Millrose Properties</a><a target="_blank" href="https://www.benzinga.com//node/43625476" rel="noreferrer noopener"> spin-off.</a>
Also, McCanless expects a 2% YoY decrease in orders to 17.8k homes for the quarter, in line with the consensus.
The analyst sees total closings of 17.2k, which is at par with Lennar&#8217;s guidance and the consensus estimate.
Also, the housing gross margin is expected at 19.1%, down 270bps YoY and in line with the company&#8217;s guidance, adds the analyst.
The analyst says that the gross margin and EPS estimates for the quarter are below consensus due to the expectation that mortgage rate volatility will likely impact Lennar&#8217;s housing gross margin and earnings negatively.
McCanless says he expects a strategy update from management as the Millrose spin-off is completed, potentially covering topics like equity investments in public stocks, Opendoor, and others.
Also, the analyst expects to get an operational update on the Millrose spin-off and any associated deal-related expenses.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Home Construction ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITB#BATS">ITB</a>) and John Hancock Fundamental All Cap Core ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHAC#NYSE">JHAC</a>).
Price Action: LEN shares are up 0.15% at $118.68 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44383094/bofa-securities-analyst-projects-millrose-spin-off-to-weigh-on-lennars-earnings-cuts-price-target" target="_blank" rel="noreferrer noopener">BofA Securities Analyst Projects Millrose Spin-Off To Weigh On Lennar&#8217;s Earnings, Cuts Price Target</a></li>
</ul>
Photo via Shutterstock.

Large Cap

iShares Dow Jones US Homenstruction Index Fund

JHAC

Analyst Takes A Cautious View On Lennar Ahead Of Q1 Earnings - Here's Why

On Wednesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) announced safety and efficacy results from the Phase 3 program for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in a broad population of patients aged two to &lt;18 years with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">spinal muscular atrophy (SMA)</a>.
In the Phase 3 STEER study, <a target="_blank" href="https://www.novartis.com/news/media-releases/new-novartis-phase-iii-data-demonstrate-meaningful-efficacy-and-safety-results-intrathecal-onasemnogene-abeparvovec-broad-patient-population-sma" rel="noreferrer noopener">treatment</a> with OAV101 IT led to a statistically significant 2.39-point improvement on the Hammersmith Functional Motor Scale Expanded (HFMSE), an assessment of motor ability and disease progression, vs. 0.51 points in the sham control arm.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43629559/novartis-to-beef-up-heart-disease-offering-with-3-billion-blackstone-backed-anthos-therapeutics-deal" rel="noreferrer noopener">Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal</a>
Novartis <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-study-meets-primary-endpoint-children-and-young-adults-sma" rel="noreferrer noopener">released</a> topline data from the Phase 3 STEER study in December 2024.
In the Phase 3b STRENGTH study, treatment with OAV101 IT in patients who have discontinued treatment with Biogen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Spinraza (nusinersen) or Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Evrysdi (risdiplam) demonstrated stabilization of motor function over 52 weeks of follow-up.
The results add to the growing body of evidence within the OAV101 IT development program, which has evaluated a broad population of over 170 patients with SMA, spanning a total of over 6.4 years across the STEER, STRENGTH, and Phase 1/2 STRONG studies.
OAV101 IT is an investigational gene replacement therapy designed to directly address the genetic root cause of the disease by replacing the nonworking&nbsp;SMN1 gene with a single dose.
In the registrational STEER study, efficacy and safety were studied in treatment naïve patients with SMA Type 2, aged two to less than 18 years, who could sit but had never walked independently. Key findings:
<ul>
<li>The trial met its primary endpoint of change from baseline to 52 weeks in HFMSE score, with OAV101 IT demonstrating a statistically significant 2.39-point improvement on the HFMSE vs 0.51 points in the sham group.</li>
<li>All secondary endpoints consistently favor OAV101 IT, despite not achieving statistical significance due to the pre-planned multiple testing procedure.</li>
</ul>
The open-label Phase 3b STRENGTH study evaluated the safety, tolerability and efficacy of OAV101 IT in patients with SMA aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam.&nbsp;Key findings:
<ul>
<li>OAV101 IT demonstrated a favorable safety profile that was consistent with the STEER study.</li>
<li>The motor endpoint of efficacy, HFMSE, demonstrated stabilization for the overall study population over 52 weeks. The increase from baseline to 52 weeks in HFMSE least squares (LS) total score was 1.05.</li>
</ul>
Price Action: NVS stock is down 0.75% at $111.38 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44397369/japan-airlines-orders-more-boeing-737-8-jets-amid-global-fleet-expansion-plans" target="_blank" rel="noreferrer noopener">Japan Airlines Orders More Boeing 737-8 Jets Amid Global Fleet Expansion Plans</a></li>
</ul>
Photo by Taljat David via Shutterstock

Biotech

Health Care

BIIB

RHHBY

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy

For many investors, the goal of achieving financial independence or building <a href="https://www.benzinga.com/personal-finance/24/10/41258919/dave-ramsey-tells-mark-cuban-75-of-the-worlds-richest-say-do-this-to-build-wealth-listen-to-them">wealth</a> in the long run focuses around strategies like dividend reinvestment plans and <a href="https://www.benzinga.com/markets/25/03/44196217/53-year-old-with-200k-to-invest-seeks-best-stocks-for-retirement-should-i-go-all-in-on-etfs-or-bet-b">ETFs</a>.
DRIPs make it possible for investors to automatically reinvest dividends into additional shares, compounding returns in time. ETFs, on the other hand, offer an accessible way to diversify across securities, reducing risk while riding on the market growth.
But how much diversification is enough, and can a single ETF provide the growth and security needed for a 40-year investment time frame? That is a question one Reddit user struggles with.
Don't Miss:
<ul>
<li>Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a></li>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
</ul>
The user, a 31-year-old sewer builder with $40,000 in an IRA and $40,000 in a Roth IRA, is considering a long-term DRIP approach using just one ETF, Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>), which holds 101 securities. His target is to maximize returns over the next 30 to 40 years, but he's skeptical about this approach providing enough diversification.
&#8220;I&#8217;d DRIP for 30-40 years (retirement ages are likely going to increase, unfortunately!) And add max out the Roth for as long as I can. Is this a bad decision? Is one ETF with 101 securities insufficient diversification?&#8221; he asked Reddit.
Reddit has offered the investor plenty of advice in the comments; let&#8217;s analyze them below.
<h2 class="wp-block-heading">$80,000 All In SCHD? Reddit Investors Offer Their Suggestions</h2>
Go for Growth Instead of Dividends in the First Few Years
Commenters emphasized that, at 31 years old, the investor should focus solely on growth-oriented investments rather than dividend-focused ones like SCHD.
&#8220;Dividends have their place, for sure. I personally would not do that! That amount of money I would put into growth only like the S&amp;P 500! Why? You will make more money in the long run through growth. You can then at retirement either sell the growth and buy dividends, which will make you a lot more money. Just have to maneuver how much to sell at a time for tax purposes. Or&#8230; just take a 4% payout, and it will be even more money payout,&#8221; a Redditor said.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Replying to the poster&#8217;s question, &#8220;Is this a bad decision?&#8221; a commenter said, &#8220;Yes. It would likely reduce your gains over 30 or 40 years by hundreds of thousands of dollars vs. investing in the S&amp;P 500. I ran the numbers with someone who had the same bad idea yesterday here.&#8221;
A Redditor suggested a hybrid approach, with most of the portfolio allocated to growth ETFs and a smaller portion to dividend assets.
&#8220;With 30 or 40 years, I&#8217;d go all in on growth. [Invesco QQQ Trust (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>)] or similar, or 80/20 with the 20% being SCHD or similar. Dividends are nice when you need them. You don&#8217;t need them because of your time horizon.&#8221;
&#8220;Nah, as good as SCHD is, the fact is, you would be missing out on some very good growth by not owning tech and growth funds,&#8221; another comment reads.
A user recommended the poster split the portfolio between three different ETFs to mix in both growth and dividends.
&#8220;It&#8217;s not the number of securities that makes it somewhat insufficient, it&#8217;s the type of securities. You&#8217;re too young to be all in SCHD. Split it evenly three ways with [SPDR S&amp;P 500 ETF Trust (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>)], QQQ, and SCHD,&#8221; he said.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
Never Go All In Into One Asset
Many Redditors disagreed with the idea of going all in into an asset, and instead, suggested diversification as a solution.
&#8220;Not everyone needs to beat the market. Wealth preservation is good and SCHD will give you a nice retirement from dividends. Don't put all your eggs in one basket,&#8221; a Redditor wrote.
&#8220;Never go all in on one thing; go a little of this, a little of that, diversity your portfolio!&#8221; one comment says.
Besides advising the poster to avoid investing all his money in only one asset, this commenter suggested a different ETF and came up with a strategy.
&#8220;Putting all your eggs in one basket is very risky, I don't care how stable the fund is. Also, if you want to constantly be paying the taxes on the income being paid every year then great, have at it. But if you ask me, you'd be better off with your time horizon and you insist on going hands-off and putting it all into one ETF, put it all into [Vanguard Total Stock Market ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vti#NYSE">VTI</a>)] and let it ride, DRIP, and keep adding to the position with any extra income. Let that nest egg grow 20 plus years, then move that much larger nest egg into SCHD later. That'll give you more income in your retirement,&#8221; he wrote.
&#8220;I wouldn't go all in. But make it a part of the portfolio that you consistently add to,&#8221; another commenter said.
Read Next:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>

Personal Finance

SCHD

Investor With $40K IRA and $40K Roth IRA Eyes 40-Year DRIP Strategy – 'Is One ETF With 101 Securities Insufficient Diversification?'

Before Elon Musk became a household name—launching rockets, revolutionizing cars, and single-handedly turning tech CEOs into celebrities—he was someone else entirely: a determined college kid in Canada awkwardly holding melting ice cream cones, relentlessly courting his future first wife, Justine Musk. In her unforgettable <a href="https://www.marieclaire.com/sex-love/a5380/millionaire-starter-wife/">2010 Marie Claire essay,</a> Justine pulls back the curtain on life with the billionaire visionary long before the world started hanging on his every tweet.
Their story took a sharp turn in late spring 2008, when Elon, <a href="https://www.benzinga.com/general/social-media/25/03/44209885/elon-musks-ex-wife-spills-the-truth-about-what-it-really-takes-to-be-a-billionaire-there-is-no-roadmap-no-blueprint-for-this">entrepreneur and father of Justine's five young sons</a>, abruptly filed for divorce. Just six weeks later, he texted that he was already engaged—to Talulah Riley, a stunning British actress in her early 20s best known for her role in 2005's "Pride and Prejudice." Justine's reaction was refreshingly honest: "Two of the things that struck me were: a) "Pride and Prejudice" is a really good movie, and b) My life with this man had devolved to a cliché." She adds dryly, "At least she wasn't blonde. I found that refreshing."
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>This Startup Is On The Brink Of A Huge Disruption To The $654 Billion Industry – <a href="https://www.benzinga.com/money/venhub-adv">Invest In It Before It Fulfills 800 Pre-Orders</a></li>
</ul>
When Justine first met Elon at Queen's University in Ontario, she wasn't exactly swept off her feet. She was an aspiring writer from a small Canadian town, fresh from a dramatic romance with a rebellious older guy who'd park his motorcycle beneath her dorm window. Elon wasn't like that—he was a clean-cut, upper-class kid with a South African accent who insisted they'd met at a party she knew she&#8217;d never attended. When he invited her out for ice cream, she agreed—but promptly blew him off. Years later, he&#8217;d confess he&#8217;d noticed her across a crowded common room and decided he needed to meet her.
But Elon, even back then, wasn&#8217;t known for accepting defeat. A few hours later, Justine heard a polite cough behind her in the overheated student lounge. Elon stood awkwardly, two chocolate-chip cones dripping down his wrists. As Justine later wrote, "<a href="https://www.benzinga.com/personal-finance/24/12/42741855/elon-musks-ex-wife-and-mother-of-5-kids-says-he-wont-take-no-for-an-answer-he-locks-his-gaze-on-to-something-and-says-it-shall-be-mine">He's not a man who takes no for an answer.</a>"
Over the years, Elon kept pursuing her, even after transferring to Wharton. Unlike previous boyfriends who dismissed her ambition as threatening or &#8220;competitive,&#8221; Elon admired it. Justine once pointed at bookstore shelves, dreaming aloud of having her own books there. Elon, unlike anyone before, took her seriously: "You have a fire in your soul," he said.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
Things escalated when Musk's first big tech venture, Zip2, took off. He was suddenly wealthy—flying Justine out to Silicon Valley for weekend visits, casually buying her endless books. Their relationship deepened quickly. But alongside romance came subtle red flags. During their wedding reception in January 2000, Elon matter-of-factly announced, &#8220;I am the alpha in this relationship.&#8221; Justine brushed it off, trusting their bond.
But wealth and success amplified those early warnings. Musk's net worth soared beyond $100 million when eBay bought PayPal in 2002, thrusting the young couple into an extravagant lifestyle filled with private jets, exclusive parties, and Hollywood glamour. Yet behind closed doors, cracks widened. Elon's drive for dominance seeped into their marriage. He frequently criticized Justine, bluntly telling her, "If you were my employee, I would fire you."
In a deeply personal reflection, Justine admits how foreign her life had become. &#8220;I barely recognized myself,&#8221; she writes. &#8220;I had turned into a trophy wife—and I sucked at it. I wasn&#8217;t detail-oriented enough to maintain a perfect house or be a perfect hostess. I could no longer hide my boredom when the men talked and the women smiled and listened.&#8221; Elon pushed her toward Hollywood perfection, urging her to go blonder, platinum even—something she stubbornly refused.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
The most devastating chapter of their story unfolded with the tragic loss of their first-born son, Nevada Alexander, at just 10 weeks old to sudden infant death syndrome. Rather than grieving together, they pulled further apart. Elon saw Justine's grief as "emotionally manipulative," pushing her to bury her pain and swiftly <a href="https://www.benzinga.com/general/entertainment/25/03/44346696/grimes-slams-elon-musk-for-putting-their-children-in-spotlight-ive-tried-begging-public-and-my-kids-dad-to-keep-them-offline">have more children</a>. IVF treatments followed quickly, producing twins and triplets. But something vital was already irreparably broken.
By 2008, their marriage quietly imploded. Justine's wake-up call came in the form of a serious car accident—a moment that crystallized just how much had unraveled. Her first instinct wasn't gratitude for survival; instead, chillingly, she thought, &#8220;My husband is going to kill me.&#8220;
Today, Justine's brutally honest reflection continues to resonate as Elon's star rises ever higher, reminding readers of the complex human story behind the headlines.
Read Next:
<ul>
<li>Hasbro, MGM Resorts, and Sketchers Use this Pre-IO AI Marketing Firm — <a href="https://www.benzinga.com/money/rad-intel">and You Can Own a Piece of it From $0.55/Share</a></li>
<li>This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a></li>
</ul>

Elon Musk's First Ex-Wife Says She 'Sucked' At Being His Trophy Wife And Recalls Him Saying: 'If You Were My Employee, I Would Fire You'

Market downturns can be both terrifying and opportunistic for investors because while some see drops as a reason to panic, others view them as a chance to buy assets at a discount.
Still, investing during a <a href="https://in.benzinga.com/etfs/broad-u-s-equity-etfs/25/02/43955914/market-could-enter-a-real-correction-expert-warns">market</a> decline is not without risks, especially when using high-risk strategies like leveraging <a href="https://in.benzinga.com/25/03/44332599/exclusive-what-industry-experts-are-saying-about-the-openai-oracle-nvidias-100b-stargate-project-etfs-that-stand-to-gain">ETFs</a> or betting heavily on a continuous downturn. One Reddit user has sparked a lively debate with his very aggressive approach to the current market.
The poster, in his 30s with nearly $1 million to invest, is betting big on a further market drop. He has already committed $370,000 to this approach, which involves selling Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) and using the proceeds to buy ProShares UltraPro QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NASDAQ">TQQQ</a>)–a 3x leveraged version of QQQ–and is willing to invest another $550,000.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>
&#8220;Normally, I hold QQQ and sell monthly calls [out of the money] with a .15 delta. Try to make 4%-7% on top with dividends. Now that TQQQ is coming down, I am selling QQQ, doing some tax loss harvesting, and buying TQQQ (1x-&gt;3x). The price target for sale is $86. Hoping the market will keep dropping. I swap 50 shares of QQQ for every 1% it drops. I estimate I&#8217;ll be out of money around 25%-35%, depending on how closely I stick to the plan,&#8221; he wrote.
But his strategy isn&#8217;t without concerns. He questions whether the market will actually drop that much, asking, &#8220;What if we don't get there?&#8221; The Reddit community had plenty to say about the investor&#8217;s strategy, so let&#8217;s dive into the comments they left.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Betting Big on Market Drop–Reddit Has a Lot to Say</h2>
Leveraged ETFs are Way Too Risky
Several commenters highlighted the fact that while many investors use leveraged ETFs to amplify their returns, they are risky and urged the poster to proceed with caution.
&#8220;Taking profits? My dude, TQQQ is going under $35 by May. I do swing trade just because of the values and % of my portfolio, but [ProShares UltraPro Short QQQ (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sqqq#NASDAQ">SQQQ</a>)] will still outperform just about any bearish tech strategy unless you just get super lucky with puts,&#8221; a commenter said.
One Redditor explained the concept of decay, which can erode returns over time, meaning that even if the market goes sideways or stabilizes, the investor&#8217;s TQQQ holdings could lose value.
&#8220;It&#8217;s called decay and it happens due to volatility (happens to everything that can be publicly traded, actually) and due to borrowing costs for the leverage. Borrowing costs increase when interest rates are higher, and decrease when interest rates are lower. So over time, even if the price of the underlying stays flat, the price of a leveraged ETF will converge to zero,&#8221; he wrote.
Another user reinforced the idea that leveraged ETFs aren&#8217;t ideal for long-term holding.
&#8220;I would be taking profits soon. S—t decays so fast,&#8221; he said.
While most comments were against the investor using this strategy, some Redditors shared they also employ this approach and agree with it.
&#8220;Wow, I actually am using the same method. I will sell 10 shares of QQQ to exchange TQQQ for every 1% drop. My average cost is $67. However, I only have $150,000 in total before the deadline,&#8221; a Reddit user shared.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Timing is Everything With High-Risk Strategies
Redditors also cautioned the investor to time the trades well by aligning them with the market momentum rather than fighting it and holding.
&#8220;You didn&#8217;t learn an even more valuable lesson: Don&#8217;t fight the momentum! The momentum has been down, down, down. Until we get economic data, policy data, and/or technical indicators that show the momentum is changing, play the momentum! You didn&#8217;t learn your lesson well. You let [fear of missing out] on a reversal (greed) determine your trade, instead of letting market momentum dictate the trade. And now you are paying the piper,&#8221; a user wrote.
A commenter offered a counterpoint, suggesting that the market may have already bottomed out.
&#8220;I think we bottomed today. There&#8217;s no real reason for the sell-off other than fear and over-leverage. It will come back in time. Per seasonality, April and May are strong months so might as well position now even if we may still be volatile in the short term,&#8221; he said.
&#8220;Once tariffs raise prices in the next months, then hit [consumer price index] and inflation pops up, then the Fed raises rates, we'll be in a longer cycle bear market and TQQQ will bottom after the sell-off. Probably 9-12 months from now,&#8221; another Redditor warned.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>

SQQQ

TQQQ

Aggressive Trader With Nearly $1M in Play Bets Big On Market Drop—'What If We Don't Get There?'—Reddit Debates His High-Risk Strategy

<h3>Gainers</h3>
<ul>
<li>TEN Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) stock moved upwards by 113.6% to $1.25 during Wednesday's regular session. The market value of their outstanding shares is at $35.2 million. </li>
<li>LZ Technology Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) shares increased by 24.47% to $11.9. The company's market cap stands at $1.8 billion. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) stock increased by 14.52% to $2.05. The market value of their outstanding shares is at $115.2 million. </li>
<li>trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) shares moved upwards by 12.82% to $4.84. The company's market cap stands at $338.5 million. </li>
<li>GCL Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) shares moved upwards by 11.36% to $2.45. The market value of their outstanding shares is at $309.3 million. </li>
<li>E W Scripps (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) shares increased by 10.95% to $3.24. The market value of their outstanding shares is at $280.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Turkcell Iletisim (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) stock decreased by 13.7% to $6.52 during Wednesday's regular session. The market value of their outstanding shares is at $5.6 billion. </li>
<li>iHuman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IH#NYSE">IH</a>) shares fell 12.27% to $2.79. The company's market cap stands at $145.6 million. </li>
<li>Reading Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDIB#NASDAQ">RDIB</a>) stock decreased by 11.62% to $8.75. The market value of their outstanding shares is at $196.2 million. </li>
<li>Lytus Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) stock declined by 11.46% to $0.06. The company's market cap stands at $1.4 million. </li>
<li>Mega Matrix (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MPU#AMEX">MPU</a>) shares fell 10.76% to $0.58. The market value of their outstanding shares is at $23.6 million. </li>
<li>John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) stock declined by 10.23% to $39.5. The market value of their outstanding shares is at $2.1 billion. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LZMH

NIPG

RDIB

TRVG

WLYB

XHLD

12 Communication Services Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock moved upwards by 17.37% to $3.35. The company's market cap stands at $2.2 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock rose 16.98% to $1.86. The market value of their outstanding shares is at $16.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 19.9% to $16.45 during Wednesday's regular session. The company's market cap stands at $91.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 17.91% to $1.88. The market value of their outstanding shares is at $28.5 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock declined by 17.54% to $83.84. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock decreased by 16.84% to $1.68. The company's market cap stands at $8.3 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares decreased by 15.84% to $2.69. The market value of their outstanding shares is at $324.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock fell 14.49% to $17.95. The company's market cap stands at $46.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BDTX

CANF

HURA

INTS

LYEL

OABI

SCNX

TNXP

VERO

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) shares increased by 28.6% to $0.5 during Wednesday's regular session. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares increased by 27.17% to $0.19. The company's market cap stands at $24.5 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock increased by 25.0% to $1.5. The market value of their outstanding shares is at $16.5 million. </li>
<li>BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) shares rose 24.22% to $4.41. The company's market cap stands at $48.6 million. </li>
<li>CDT Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) shares rose 18.12% to $1.89. The market value of their outstanding shares is at $20.2 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares increased by 15.24% to $1.89. The market value of their outstanding shares is at $28.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares decreased by 16.5% to $0.18 during Wednesday's regular session. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock decreased by 15.47% to $0.35. The market value of their outstanding shares is at $10.5 million. </li>
<li>Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) stock decreased by 11.22% to $14.65. The company's market cap stands at $65.7 million. As per the press release, Q4 earnings came out today. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares fell 10.72% to $0.55. The market value of their outstanding shares is at $197.7 million. </li>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) stock decreased by 10.2% to $0.93. The market value of their outstanding shares is at $38.5 million. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) stock decreased by 9.51% to $0.79. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

ATXG

BGSF

BTOC

CDTG

CLIK

HKPD

SUNE

TISI

VSTE

12 Industrials Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) stock moved upwards by 31.4% to $7.32 during Wednesday's regular session. The company's market cap stands at $113.1 million. </li>
<li>Exodus Movement (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#AMEX">EXOD</a>) shares increased by 30.0% to $39.34. The company's market cap stands at $1.1 billion. </li>
<li>Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) shares increased by 14.5% to $5.13. The market value of their outstanding shares is at $330.2 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) stock rose 14.17% to $3.06. The market value of their outstanding shares is at $164.8 million. The company's, Q4 earnings came out today. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) stock rose 13.73% to $1.82. The market value of their outstanding shares is at $22.7 million. </li>
<li>Castellum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTM#AMEX">CTM</a>) shares moved upwards by 13.35% to $1.28. The company's market cap stands at $102.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares declined by 37.7% to $0.25 during Wednesday's regular session. The company's market cap stands at $11.3 million. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) shares fell 22.44% to $0.62. The market value of their outstanding shares is at $8.9 million. </li>
<li>One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) shares declined by 20.1% to $2.44. The market value of their outstanding shares is at $51.6 million. As per the press release, Q4 earnings came out today. </li>
<li>GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock fell 13.53% to $30.77. The company's market cap stands at $5.9 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock decreased by 10.21% to $2.2. The company's market cap stands at $14.5 million. </li>
<li>Tungray Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares declined by 9.8% to $1.29. The company's market cap stands at $21.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEVA

AMOD

CISO

CSAI

EXOD

MOVE

TRSG

XNET

12 Information Technology Stocks Moving In Wednesday's Intraday Session

Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) stock is rebounding today. This comes after yesterday's sell-off of 7.3%. The company will be reporting its first-quarter results on Friday. 
Royal Caribbean is our Stock of the Day.
Some people are proponents of the Random Walk Theory. This theory states stock prices are random. This means past movements and trends cannot be used to predict a stock's future movement.
Random Walk also says it is impossible for an investor to beat the market.
This theory is easily proved to be false. If it was true, every price level in the market would have the same amount of importance. Support and resistance levels would not exist. But clearly, they do.
This can be seen on the chart of Royal Caribbean.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="940" height="510" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19125340/1-6.png" alt="" class="wp-image-832079" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19125340/1-6.png 940w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19125340/1-6-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19125340/1-6-768x417.png 768w" sizes="(max-width: 940px) 100vw, 940px" /></figure>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44393145/anthony-scaramucci-says-trump-administration-has-smarter-people-involved-with-crypto-regulation">Anthony Scaramucci Says Trump Administration Has &#8216;Smarter&#8217; People Involved With Crypto Regulation</a>
The stock recently rallied. But the rally ended when it ran into resistance — or a large group of sellers — around the $220 level.
This wasn't a coincidence. The price action wasn't random at all.
The reason why there was resistance at this level is because it had previously been a support level. Support levels converting into resistance levels is a common occurrence in the stock market.
It is because some of the people who bought shares around $220 in January came to think they made a mistake when the support broke on March 6 and the price fell lower. Many of them decided to hold onto their losing positions. But they vowed to sell if they could eventually do so at breakeven.
As a result, when Royal Caribbean rallied back up to $220, these remorseful buyers flooded the market with sell orders. The large amount of these orders formed resistance at the same price that had previously been support.
It wasn't random.
If Royal Caribbean continues to move higher, there is a good chance it could stall out around $220 again. Savvy traders know that a level that has been important in the past can become so again in the future.
Read Also: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44399554/analysts-see-upside-for-95-of-sp-500-stocks-how-nvidia-tesla-stack-up">Analysts See Upside For 95% Of S&amp;P 500 Stocks: How Nvidia, Tesla Stack Up</a>

Courtesy: Royal Caribbean

Technicals

Travel

Stock Of The Day: Royal Caribbean Rally Could End At This Price

MSFT

CNBC Halftime Report Final Trades: Microsoft, Morgan Stanley and CRH

Susquehanna analyst Christopher Rolland maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Positive and maintains $180 price target.

NVDA

Susquehanna Maintains Positive on NVIDIA, Maintains $180 Price Target

Charles Schwab's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) short percent of float has fallen 26.12% since its last report. The company recently reported that it has 16.84 million shares sold short, which is 0.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Charles Schwab Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742403628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Charles Schwab has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Charles Schwab's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Charles Schwab's peer group average for short interest as a percentage of float is 3.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SCHW

Is the Market Bullish or Bearish on Charles Schwab?

Aramark's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) short percent of float has risen 8.05% since its last report. The company recently reported that it has 4.96 million shares sold short, which is 1.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Aramark Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742403623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Aramark has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Aramark's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Aramark's peer group average for short interest as a percentage of float is 10.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ARMK

Is the Market Bullish or Bearish on Aramark?

Halliburton's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) short percent of float has fallen 19.08% since its last report. The company recently reported that it has 20.50 million shares sold short, which is 3.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Halliburton Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742403618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Halliburton has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Halliburton's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Halliburton's peer group average for short interest as a percentage of float is 8.01%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Halliburton?

Press Releases

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSTK, AKYA, POAI on Behalf of Shareholders

Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner

Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences

Earnings

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

Comments

Akoya Biosciences

Noticias

Últimas noticias sobre Akoya Biosciences (NASDAQ:AKYA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL